Beyond Use Dating — Apply beyond-use dating standards to compounded preparations

The concept of beyond-use dating (BUD) arose from a fundamental patient-safety concern: unlike commercially manufactured drugs that undergo extensive stability testing and receive FDA-approved expiration dates, compounded preparations are made in smaller quantities without the same rigorous shelf-life data. Historically, pharmacists relied on professional judgment and limited guidance to determine how long a compounded product remained safe and effective after preparation. Several high-profile contamination events in the late twentieth and early twenty-first centuries — most notably the 2012 New England Compounding Center (NECC) meningitis outbreak — underscored the dangers of inadequate quality controls, including poorly assigned beyond-use dates. These events catalyzed sweeping regulatory reforms in pharmacy compounding standards, particularly within the United States Pharmacopeia (USP) framework.

The central question driving all of these developments is deceptively simple: How long after compounding can a preparation be expected to retain its identity, strength, quality, and purity? Answering this question requires an understanding of chemical stability, microbial contamination risk, storage conditions, and the regulatory frameworks that govern compounding practice. For MPJE candidates, mastery of BUD standards is essential because state boards of pharmacy enforce these standards as a matter of public health protection, and violations can result in disciplinary action, pharmacy closure, or criminal liability.

Before examining specific BUD standards, it is critical to distinguish between related but legally distinct concepts. A beyond-use date is the date or time after which a compounded preparation shall not be used, stored, or transported; it is determined by the compounder and begins at the time of compounding. In contrast, an expiration date is assigned by the manufacturer of a commercially available drug product based on FDA-mandated stability studies. These terms are not interchangeable. Compounded preparations receive BUDs, not expiration dates, because they have not undergone the same stability-indicating assays required for NDA or ANDA approval.

Assigning a beyond-use date involves a structured decision process that accounts for the type of preparation (sterile vs. nonsterile), the source of stability data, storage conditions, and the applicable USP chapter. The following diagram provides a high-level decision flowchart that a compounding pharmacist follows when determining the appropriate BUD for a given preparation.

As shown in the diagram, the decision framework begins with identifying whether the preparation is sterile or nonsterile. For nonsterile preparations under USP <795>, the pharmacist evaluates whether published stability data or direct testing results support a specific BUD; if not, conservative default limits apply. For sterile preparations under USP <797>, the preparation is classified as Category 1 or Category 2 based on the conditions under which it was compounded, with Category 2 requiring more stringent environmental controls and testing to support longer BUDs. Regardless of the pathway, the BUD can never exceed the earliest expiration date of any component ingredient — a critical constraint that appears in both USP chapters.

Nonsterile Compounding — USP <795> Default BUDs

Under the revised USP <795>, when no stability data is available, the pharmacist must apply default beyond-use dates that are deliberately conservative. These defaults vary by dosage form because different physical states present different stability profiles. Aqueous solutions and suspensions are more susceptible to microbial growth and hydrolytic degradation than solid dosage forms, so they receive shorter default BUDs. If the compounder has stability-indicating data from published literature, direct testing, or a stability study performed per USP guidelines, the BUD may be extended beyond the default — but it must still not exceed the earliest expiration date of any ingredient. The guiding principle is that the BUD represents the period during which at least 90% of the labeled potency is retained and the preparation remains within all specified quality attributes.

Sterile Compounding — USP <797> Categories

The revised USP <797> replaced the former low-risk, medium-risk, and high-risk classification system with two categories. Category 1 CSPs are compounded under conditions that do not meet all Category 2 requirements and therefore receive shorter default BUDs. Category 2 CSPs are prepared in facilities that meet stringent environmental monitoring, personnel qualification, and testing requirements, permitting longer BUDs. The distinction between the two categories hinges on factors such as the cleanliness classification of the compounding area, the use of ISO Class 5 primary engineering controls, the availability of sterility testing, and endotoxin testing for high-risk routes of administration.

Understanding the differences between Category 1 and Category 2 CSPs is one of the most frequently tested topics on the MPJE with respect to compounding law. The distinction is not merely about the length of the BUD — it reflects a fundamentally different level of quality assurance infrastructure. Category 2 facilities invest in ISO-classified cleanrooms, conduct environmental monitoring with viable and nonviable sampling, perform media-fill testing of personnel, and may conduct sterility testing on finished preparations. Category 1 operations, by contrast, often involve hospital or community pharmacy settings where compounding occurs in an ISO Class 5 hood located within a less rigorously classified area, and where the preparations are intended for prompt administration.

The visual comparison above highlights that a Category 1 CSP compounded at room temperature has a maximum BUD of only 12 hours, while a Category 2 CSP stored at room temperature can be assigned up to 28 days. This dramatic difference underscores a core principle of compounding regulation: longer storage requires proportionally greater evidence of safety. A hospital that prepares IV admixtures for same-day use operates under Category 1, while a 503B outsourcing facility shipping products across state lines must meet Category 2 standards. Students should note that these default BUD limits may be further extended with appropriate stability-indicating testing, but the defaults function as the maximum when such data is absent.

Consider the following scenario: A community pharmacy compounds a nonsterile oral suspension of omeprazole 2 mg/mL using omeprazole capsules (expiration date: September 2025), sodium bicarbonate 8.4% solution (expiration date: December 2025), and purified water (no expiration date on container). The pharmacy does not have access to stability-indicating testing. The final suspension will be stored under refrigeration. What beyond-use date should be assigned?

Pharmacy students and MPJE candidates frequently confuse beyond-use dates with expiration dates, or misapply BUD rules across different compounding contexts. The following table clarifies the critical distinctions and highlights common regulatory pitfalls that arise in practice and on examinations.

While USP chapters provide the scientific foundation for BUD assignment, the regulatory landscape extends well beyond USP standards. The Drug Quality and Security Act (DQSA) created a two-tier system: Section 503A governs traditional compounding pharmacies that compound pursuant to individual prescriptions, while Section 503B governs outsourcing facilities that may compound without patient-specific prescriptions and are subject to FDA current Good Manufacturing Practice (cGMP) inspections. Outsourcing facilities operating under 503B may use stability-indicating methods such as high-performance liquid chromatography (HPLC) to support extended BUDs far beyond USP defaults, provided their testing protocols satisfy cGMP requirements. This represents the advanced frontier of BUD science, where analytical chemistry and regulatory law intersect.

MPJE candidates must also recognize that state boards of pharmacy may impose BUD requirements that are more restrictive than USP standards. For example, a state may require all CSPs to carry BUDs no longer than Category 1 limits unless the pharmacy has obtained a specific sterile compounding permit and undergone an inspection. Similarly, some states may not yet have adopted the revised USP <797> categories and continue to reference the older risk-level classifications. When USP standards and state law conflict, the more stringent requirement always governs. Pharmacists must be familiar with both federal and state-specific BUD requirements, which is precisely why this topic appears so prominently on the MPJE.